Hiroomi Tada

2023

In 2023, Hiroomi Tada earned a total compensation of $2.4M as Chief Medical Officer at Tyra Biosciences, a 90% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$305,760
Option Awards$1,596,107
Salary$509,600
Other$950
Total$2,412,417

Tada received $1.6M in option awards, accounting for 66% of the total pay in 2023.

Tada also received $305.8K in non-equity incentive plan, $509.6K in salary and $950 in other compensation.

Rankings

In 2023, Hiroomi Tada's compensation ranked 415th out of 2,918 executives tracked by ExecPay. In other words, Tada earned more than 85.8% of executives.

ClassificationRankingPercentile
All
415
out of 2,918
86th
Division
Manufacturing
238
out of 1,608
85th
Major group
Chemicals And Allied Products
169
out of 901
81st
Industry group
Drugs
166
out of 864
81st
Industry
Pharmaceutical Preparations
104
out of 622
83rd
Source: SEC filing on April 18, 2024.

Tada's colleagues

We found two more compensation records of executives who worked with Hiroomi Tada at Tyra Biosciences in 2023.

2023

Todd Harris

Tyra Biosciences

Chief Executive Officer

2023

Alan Fuhrman

Tyra Biosciences

Chief Financial Officer

News

In-depth

You may also like